Collaborative group phase III study shows Roche’s Avastin improves survival in patients with mesothelioma - a devastating type of thoracic cancer

Roche announced today phase III results from a collaborative group study that showed that patients with malignant pleural mesothelioma, a rare type of cancer that affects the lining of the lungs, lived significantly longer when treated with Avastin in combination with standard therapy (pemetrexed and cisplatin chemotherapy) compared to standard therapy alone.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news